Lundbeck / Chief Medical Officer, VP, NA R&D / North America Research and Development
Doug Williamson, MBChB; MRCPsych is Chief Medical Officer and VP, NA R&D for Lundbeck. He received his medical degree at the University of Edinburgh in Scotland and was subsequently admitted to Membership of the Royal College of Psychiatrists. He served as an MRC Clinical Scientist at the University of Oxford Department of Psychopharmacology, where he studied neuroendocrine responses to antidepressant treatment and treatment resistant depression, prior to joining Eli Lilly in the UK. He was transferred to Lilly’s Corporate Center in Indianapolis in 1999 to lead the development of a combination of olanzapine and fluoxetine for treatment resistant depression and bipolar depression, and also led the global regulatory approval of olanzapine for maintenance treatment of bipolar disorder. Dr. Williamson subsequently led Lilly’s US Medical Affairs group for depression products (including duloxetine) for several years. His final years at Lilly were spent overseeing the early phase neuroscience clinical development program as Senior Medical Director, leading a team mainly focused on developing proof of concept studies for novel pipeline compounds. He joined Parexel, a global CRO, in 2012 serving initially as Global Therapeutic Lead for Psychiatry, before being promoted to Vice President across all Therapeutic Areas.
Dr. Williamson joined Lundbeck in 2016, where he leads the North America Research and Development Organization and is a member of the Global R&D Executive Committee, as well as the Governance Committees for Lundbeck’s partnerships with Otsuka and Takeda.